Quantification of soluble-form signaling lymphocytic activation molecule family 7 (SLAMF7) and comprehensive gene expression analysis in serum samples among patients with relapsed/refractory multiple myeloma (RRMM): A multicenter prospective observational study (FBMTG RRMM18).

Quantification of soluble-form signaling lymphocytic activation molecule family 7 (SLAMF7) and comprehensive gene expression analysis in serum samples among patients with relapsed/refractory multiple myeloma (RRMM): A multicenter prospective observational study (FBMTG RRMM18). - Quantification of SLAMF7 and comprehensive gene expression analysis in serum samples among patients with RRMM:(FBMTG RRMM18).

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037176

Enrollment

100

Registered

2019-07-01

Start date

2019-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

multiple myeloma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. RRMM patients based on IMW definition. 2. Age of 20 to 85 years. 3. Treated with 1-3 lines of prior chemo-radiotherapy (and remained effective salvage treatment). 4. Signed consent form to participate in this study.

Exclusion criteria

Exclusion criteria: 1. Treated with >=4 lines of prior chemo-radiotherapy. 2. Diagnosed as solitary plasmacytoma, plasma cell leukemia, or POEMS syndrome. 3. Positive results of either HIV-antibody, HBs-antigen, or HCV-antibody(except for HCV-PCR negativity). 4. Uncontrolled following diseases:liver dysfunction, renal dysfunction, cardiac dysfunction, respiratory dysfunction, diabetes, hypertension, infection. 5. Active advanced double-cancer (concurrently existed or <=5 years of disease free period, excluding Carcinoma in situ at uterine cervix, stomach, or colon). 6. Severe mental disorders such as schizophremia. 7. Pregnant women, possible of pregnancy, or during lactation. 8. Judged as inappropriate to participate in this study by doctor.

Design outcomes

Primary

Measure	Time frame
Serum sSLAMF7 level and its indicative value for treatment response or prognosis among RRMM patients.	—

Countries

Japan

Contacts

Public ContactStudy Office FBMTG

Fukuoka Blood and Marrow Transplant Group FBMTG Study Office

fbmtg@intmed1.med.kyushu-u.ac.jp092-642-5315

Outcome results